Understanding how prostate cancer cells change and become harder to treat
Targeting early events in prostate cancer lineage plasticity
This study is looking at how prostate cancer cells change when treated with hormone-blocking therapies, which can make them harder to treat, and it aims to find new ways to stop or reverse these changes to help patients with advanced prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10993102 on NIH RePORTER |
What this research studies
This research investigates how prostate cancer cells adapt and change when treated with therapies that block male hormones, specifically focusing on a process called lineage plasticity. When prostate cancer cells become resistant to treatment, they can transform into different cell types that are more difficult to target with existing therapies. The study aims to uncover the biological mechanisms behind this transformation and to develop new treatment strategies that could prevent or reverse these changes. By analyzing the role of specific transcription factors in this process, the research hopes to identify potential therapeutic targets for patients with advanced prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer who are undergoing or have undergone androgen deprivation therapy.
Not a fit: Patients with early-stage prostate cancer or those who do not have advanced disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with advanced prostate cancer that has become resistant to current therapies.
How similar studies have performed: Other research has shown promise in understanding cancer cell plasticity, but this specific approach to targeting lineage plasticity in prostate cancer is relatively novel.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Dehm, Scott M. — University of Minnesota
- Study coordinator: Dehm, Scott M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.